Billionaire Israel "Izzy" Englander Has Loaded Up on This Dividend King. Should You?

Billionaire investor Izzy Englander's Millennium Management aggressively boosted its stake in pharmaceutical giant AbbVie (ABBV) by 416% in Q2 2025. This substantial investment in the 'Dividend King' is likely driven by AbbVie's successful navigation of the Humira patent cliff with strong successor drugs like Skyrizi and Rinvoq, a robust pipeline of 90 programs, and an attractive valuation, with the stock having already risen approximately 20% since the end of Q2.

Analysis

Billionaire investor Israel Englander's Millennium Management significantly increased its stake in AbbVie (ABBV) by 416% during Q2 2025, signaling strong conviction in the pharmaceutical giant. This substantial investment targets a "Dividend King" known for 53 consecutive years of dividend increases, underscoring its appeal as an income-generating asset.

AbbVie has effectively navigated the Humira patent cliff, with successor drugs Skyrizi and Rinvoq projected to generate over $25 billion in combined sales this year, surpassing Humira's peak of $21 billion. The company also reported double-digit year-over-year sales growth in Q2 for key products like Qulipta and Ubrelvy, demonstrating robust operational performance beyond its former blockbuster.

The aggressive stake increase likely reflects AbbVie's deep pipeline, comprising approximately 90 programs, with about 50 in mid-to-late-stage clinical testing, promising future growth. Furthermore, the stock's attractive forward P/E ratio of 16.8, which was even lower during Englander's Q2 purchases, suggests a compelling valuation, especially given the stock's subsequent ~20% appreciation.

Key Decisions for Investors

• Investors should evaluate AbbVie's long-term growth prospects, particularly the sales trajectory of Skyrizi and Rinvoq, as these are critical for post-Humira revenue stability.
• Consider the company's robust R&D pipeline as a key driver for sustained innovation and future revenue streams, assessing the potential of its 90 programs.
• Monitor AbbVie's valuation metrics, especially its forward P/E ratio and dividend yield of 2.9%, to determine if the stock still offers an attractive entry point following its recent ~20% price appreciation.